Skip to content
lifestyle.projectdiaspora.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nurix Therapeutics, Inc.
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
November 11, 2026
Nurix Therapeutics to Participate in Upcoming Investor Conferences
November 10, 2026
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
November 5, 2026
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
November 3, 2026
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
October 12, 2026
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
October 7, 2026
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
October 5, 2026
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
September 29, 2026
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
September 1, 2026
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
August 20, 2026
1
2
Next Page
→